Immunohistochemistry of resected tumours showed CT7001 monotherapy reduced Ki67 expression, with further decrease observed in tumours treated with a combination of enzalutamide and CT7001 (Fig. 5g and Supplementary Fig. S5D). Here, MKI67 is linked to neoplasm.